SION Company Profile and Key Details

SION has shown sold momentum, gaining 10.1% over the past week and 25.31% over the past quarter, though year-to-date performance is down -2.75%. Short-term trend indicators are mixed aligned (SMA20 -1.31%, SMA50 -5.29%, SMA200 30.8%). The stock’s 14-day RSI is 48.01 (neutral), while the ATR of 2.72 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -15.56% below its high and over 423.78% above its low. Average 10-day trading volume of 486.36 thousand shares is slightly above the 3-month average of 437.21 thousand, indicating heightened recent market interest.

Sionna Therapeutics, Inc. has 44.14 million shares outstanding. The public float is 11.04 million shares, elevated short interest at 13.71% of float. This equals 3.60 million shares. The short ratio is 22.4 days. Institutional investors hold 107.65% of the float. Insiders own 6.85%. TPG GP A, LLC holds 6.49 million shares, ORBIMED ADVISORS LLC has 2.47 million shares and Thompson Peter A. has 2.47 million shares. Over the past six months, insider transactions show net selling. They sold 2.45 million shares across 29 transactions.

Sionna Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.25. This means the shares are trading above this model’s fair value.

Wall Street analysts project EPS growth of 45.13% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 5 Strong Buy ratings, 11 Buy ratings, 2 Hold ratings, 0 Sell rating and 1 Strong Sell ratings. Price targets range from $63.00 to $22.00. The high target offers 43.34% upside. The low target suggests -49.94% downside. The mean target is $50.53. This offers 14.97% upside. Sionna Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended May 12, 2026, missed forecasts by 15.38%. The prior quarter beat by -14.66%. Over the last six quarters, Apple has recorded several small beats. These include 492.98% in March 20, 2025.

Sionna Therapeutics, Inc. (NASDAQ:SION) closed at $43.95 USD, losing -$1.34 (-2.96%) from the previous close of $45.29. The stock is currently mid-range between its 52-week high and low $16.38 and $48.45. With a market capitalization of about $1.98 billion, Sionna Therapeutics, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~1.32). Key stats such as the average daily volume over the past year has been around 446.85 thousand shares, in line with its 52-week average. Headquartered in Waltham, MA, Sionna Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Michael Cloonan, the company employs approximately 59 people and listed since February 07, 2025. Operating as a biopharmaceutical company, Sionna Therapeutics, Inc. is dedicated to transforming the treatment landscape for individuals with cystic fibrosis.

Sionna Therapeutics, Inc. trades at a P/E ratio of -22.73, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 6.84 trading at moderately above to book value. The P/FCF stands at -27.46, also below market averages.

Sionna Therapeutics, Inc. (NASDAQ:SION) shares are flat -2.75% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Sionna Therapeutics, Inc. trading at a premium to the broader market with a P/E of -22.73. Analyst sentiment is cautious, with the majority of ratings in Market Outperform territory and a mean price target of $49.60, suggesting 12.86% upside. Our AI forecast model points to short-term strength (11.97% over two weeks), a medium-term fall (-0.2% over three months), and a longer-term gain (71.35% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Sionna Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 11.97%, with price expected at $49.21 by July 27, 2026, within a range of $46.84 to $51.52 3-Month Outlook: Projected fall of -0.2%, reaching $43.86 by October 08, 2026, with a range of $43.02 to $44.71. 1-Year Outlook: Projected gain of 71.35%, with price at $75.31 by July 13, 2027, within a range of $73.34 to $77.03.